Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Metabolism and nutrition disorders – page 40

  • 741 clinical trials
  • 263 recruiting
  • 237 conditions
  • 26 countries

Conditions in this area

237 conditions with trials, the busiest first

Obesity116Type 2 diabetes mellitus83Overweight51Type 1 diabetes mellitus38Endocrine ophthalmopathy26Metabolic dysfunction-associated steatohepatitis22Diabetes mellitus21Non-alcoholic steatohepatitis17Type IIa hyperlipidaemia15Glycogen storage disease type II14Hypercholesterolaemia14Diabetic foot13Diabetic retinal oedema13Diabetic neuropathy12Alpha-1 antitrypsin deficiency11Chronic kidney disease10Fabry's disease10Osteoporosis10Hypertriglyceridaemia9Hypoparathyroidism9Acromegaly8Dyslipidaemia8Iron deficiency8Phenylketonuria8+213

Clinical trials in Metabolism and nutrition disorders

741 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

741 clinical trials

Type 2 diabetes mellitus

Not recruiting

Study on Insulin Aspart for Recovery from Low Blood Sugar in People with and without Type 2 Diabetes

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · Healthy volunteers
  • Substances:Insulin Aspart
  • Sponsor:Medical University Of Graz

Obesity+1

Not recruiting

Study on the Effects of RO7204239 and Tirzepatide for Weight Loss in Patients with Obesity or Overweight with a Weight-Related Health Issue

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Tirzepatide
  • Sponsor:F. Hoffmann-La Roche AG

Endocrine ophthalmopathy

Not recruiting

Study on the Safety and Tolerability of VRDN-003 for Patients with Thyroid Eye Disease

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:VRDN-003
  • Sponsor:Viridian Therapeutics Inc.

Obesity+1

Not recruiting

Study on Maridebart Cafraglutide for Adults with Type 2 Diabetes and Obesity or Overweight

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Endocrine ophthalmopathy

Not recruiting

Study on the Effectiveness and Safety of VRDN-003 for Patients with Chronic Thyroid Eye Disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:VRDN-003
  • Sponsor:Viridian Therapeutics Inc.

MELAS syndrome

Not recruiting

Study on the Safety and Effectiveness of Zagociguat for Treating MELAS in Patients

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Zagociguat
  • Sponsor:Tisento Therapeutics Inc.

Hyponatraemia

Not recruiting

Study on the Effects of Empagliflozin in Patients with Euvolemic and Hypervolemic Hyponatremia

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Empagliflozin
  • Sponsor:Universitaetsspital Basel

Type 2 diabetes mellitus

Not recruiting

Study on Personalized Treatment Using Dapagliflozin, Dulaglutide, and Metformin for Patients with Uncontrolled Type 2 Diabetes

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Canagliflozin
  • Sponsor:Instituto De Investigacion Sanitaria Fundacion Para La Investigacion Del Hospital Clinico De Valencia-INCLIVA

Type 2 diabetes mellitus+1

Not recruiting

Study on the Effectiveness of Survodutide for Weight Loss in Patients with Type 2 Diabetes and Obesity

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:BI 456906
  • Sponsor:Boehringer Ingelheim Espana S.A.

Obesity

Not recruiting

Study on the Effectiveness of Survodutide for Weight Loss in Adults with Obesity Without Diabetes

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:BI 456906
  • Sponsor:Boehringer Ingelheim International GmbH

MELAS syndrome

Not recruiting

Long-term safety study of zagociguat tablets in patients with MELAS syndrome (Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes) who completed previous trial

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Zagociguat
  • Sponsor:Tisento Therapeutics Inc.

Obesity

Not recruiting

Study on How Cagrilintide and Semaglutide Help People with Overweight or Obesity Reduce Weight

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:Novo Nordisk A/S

Substances studied in this area

The therapies tested most often in Metabolism and nutrition disorders trials.

Semaglutide76 clinical trialsSodium Chloride25 clinical trialsDapagliflozin23 clinical trialsEmpagliflozin16 clinical trialsCagrilintide15 clinical trialsPlacebo15 clinical trialsColecalciferol14 clinical trialsTirzepatide13 clinical trialsParacetamol12 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.